Analysts Offer Insights on Healthcare Companies: Tocagen Inc (NASDAQ: TOCA), Pacira Pharmaceuticals (NASDAQ: PCRX) and Catalyst Pharma (NASDAQ: CPRX)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tocagen Inc (TOCAResearch Report), Pacira Pharmaceuticals (PCRXResearch Report) and Catalyst Pharma (CPRXResearch Report) with bullish sentiments.

Tocagen Inc (TOCA)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Tocagen Inc today and set a price target of $14.50. The company’s shares closed yesterday at $5.08, close to its 52-week low of $4.13.

Ramakanth observed:

“We maintain our Buy rating of Tocagen and our 12-month price target of $14.50 per diluted share. We derive our price target based on a risk-adjusted NPV analysis of projected Toca 511 + Toca FC revenues through 2030, assuming a 12% discount rate and a 2% terminal growth rate.”

According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -11.6% and a 29.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Gritstone Oncology Inc, and Trillium Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tocagen Inc with a $16.30 average price target.

See today’s analyst top recommended stocks >>

Pacira Pharmaceuticals (PCRX)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $60. The company’s shares closed yesterday at $42.36.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 6.7% and a 50.7% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Zynerba Pharmaceuticals.

Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $59.33, which is a 40.1% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $85 price target.

Catalyst Pharma (CPRX)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Catalyst Pharma today and set a price target of $9. The company’s shares closed yesterday at $5.08.

Fein said:

“Our price target of $9/share is based on an equally weighted composite of: (a) $9.36/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.80 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2019-2024 of $8.96/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”

According to TipRanks.com, Fein is a 3-star analyst with an average return of 1.1% and a 40.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalyst Pharma with a $9.33 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.